Healthcare >> CEO Interviews >> November 8, 2001
ALAN J. MAIN has been Senior Vice President of Lexicon Pharmaceuticals
since July 2001 following the acquisition of Coelacanth Corporation by
Lexicon Genetics. Dr. Main held the position of President and CEO with
Coelacanth Corporation, based in East Windsor, New Jersey, from January
1, 2000. Prior to this, Dr. Main held the position of Senior Vice
President of US Research for Novartis Pharmaceuticals Corporation,
Summit, New Jersey, from 1997 -1999. He has a PhD degree in Organic
Chemistry from Liverpool University in England and completed a Post-
doctoral Research Fellowship at the Woodward Research Institute in
Basel, Switzerland, studying with the Nobel Laureate in Chemistry, Prof.
R. B. Woodward. He then moved to the Pharmaceutical Division of Ciba-
Geigy in Summit, New Jersey, where he held positions of increasing
responsibility in the Medicinal Chemistry and Arthritis areas. In 1992,
he was appointed Senior Vice President for Research and Preclinical
Development for Ciba Pharmaceuticals, a position he held until the
merger with Sandoz Pharmaceuticals in 1997. Dr. Main is a Fellow of the
Royal Society of Chemistry, and has served as a Board member of a number
of research-based organizations including: the New Jersey Research and
Development Council, the Biotechnology Council of New Jersey, the
Inflammation Research Association and Myriad Genetics Inc. Profile
Pharmaceuticals?
Dr. Main: Lexicon Pharmaceuticals was actually created only this summer,
in July 2001, through the merger of
